Combivir

Treatment of HIV Infection

Combivir is used to treat HIV infection in adults and children who weigh at least 30 kilograms (about 66 pounds). It contains two active ingredients, lamivudine and zidovudine, which belong to a class of medications known as nucleoside reverse transcriptase inhibitors (NRTIs).

Goals of Therapy

This medication is always used in combination with at least one other antiretroviral drug. When used as part of a complete treatment regimen, the goals include:

• Reducing the amount of HIV in the blood (viral load).
• Helping the immune system recover or maintain its function by increasing the count of infection-fighting cells.
• Lowering the risk of developing complications or opportunistic infections related to HIV.

Important Considerations

Combivir is not a cure for HIV or acquired immunodeficiency syndrome (AIDS). While it helps manage the virus, it does not prevent the transmission of HIV to others through sexual contact or exposure to blood. Patients taking this medication may still develop health problems or infections associated with HIV infection, and they must remain under the regular care of a healthcare provider.

Mechanism of Action

Combivir is a combination of two antiviral medications: lamivudine and zidovudine. Both of these drugs belong to a class of medicines known as nucleoside reverse transcriptase inhibitors (NRTIs).

HIV uses an enzyme called reverse transcriptase to convert its genetic material (RNA) into DNA. This process is necessary for the virus to multiply and infect new cells in the body. The medications in Combivir work by:

• Mimicking the natural building blocks that the virus uses to create DNA.
• Interrupting the DNA-building process, which prevents the virus from making complete copies of itself.

Effects on the Body

By slowing down the production of new virus particles, Combivir helps reduce the total amount of HIV in the blood. While it is not a cure for HIV or AIDS, lowering the viral load allows the immune system to function more effectively and may increase the number of CD4 (T-helper) cells, which are vital for fighting infections.

Common Side Effects

Many people taking this medication experience mild side effects. These may include:

• Headache or dizziness
• Nausea, vomiting, or diarrhea
• Fatigue or general weakness
• Loss of appetite
• Cough or nasal congestion
• Difficulty sleeping

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact a healthcare provider if you experience:

• Blood disorders: Signs of anemia, such as extreme tiredness, pale skin, and shortness of breath, or signs of low white blood cell counts, such as fever, chills, and sore throat.
• Liver problems: Yellowing of the skin or eyes (jaundice), dark-colored urine, light-colored stools, or pain in the upper right stomach area.
• Lactic acidosis: Unusual muscle pain, feeling cold, dizziness, or a fast or irregular heartbeat.
• Pancreatitis: Severe pain in the upper stomach that may spread to the back, often accompanied by nausea and vomiting.
• Muscle weakness: Persistent or worsening muscle aches and weakness.
• Changes in body fat: Redistribution or accumulation of body fat in areas like the neck, back, or trunk.

In some cases, the immune system may become overactive after starting treatment, which can cause old or hidden infections to flare up. This is known as immune reconstitution syndrome.

Boxed Warnings

Combivir has several serious warnings that require close medical supervision:

• Lactic Acidosis and Liver Problems: A buildup of lactic acid in the blood (lactic acidosis) and severe liver enlargement with fatty deposits (steatosis) have been reported. These conditions can be life-threatening and may occur even without abnormal liver tests.
• Hepatitis B Exacerbation: In patients with both HIV and hepatitis B (HBV), the HBV infection may worsen significantly if Combivir is stopped. Liver function should be monitored closely for several months after discontinuing treatment.
• Blood Toxicity: Zidovudine, one of the components in Combivir, can cause low red blood cell counts (anemia) and low white blood cell counts (neutropenia). This is more common in patients with advanced HIV. Frequent blood tests are usually necessary to monitor these levels.
• Muscle Weakness: Long-term use of zidovudine has been linked to muscle wasting or weakness, known as myopathy.

Other Precautions

Immune Reconstitution Syndrome

As the immune system strengthens during treatment, it may react strongly to previously hidden or inactive infections, such as pneumonia or tuberculosis. This can cause new symptoms or a flare-up of old infections shortly after starting therapy.

Fat Redistribution

Changes in body fat distribution may occur in patients receiving antiretroviral therapy. This can include the loss of fat from the legs, arms, and face, or the accumulation of fat in the neck, upper back, and trunk.

Pancreatitis

Inflammation of the pancreas (pancreatitis) has occurred in some patients taking the components of Combivir. This risk may be higher in children or individuals with a history of pancreatic issues. Treatment may need to be suspended if symptoms of pancreatitis develop.

Kidney and Liver Function

Because Combivir is a fixed-dose combination, it may not be appropriate for individuals with significant kidney or liver impairment. These patients often require specific dose adjustments of the individual medications that cannot be achieved with the combined tablet.

Pregnancy

Healthcare providers often prescribe Combivir during pregnancy because managing HIV is critical for the health of the parent and for reducing the risk of transmitting the virus to the baby. While human studies have not established a clear link between Combivir and birth defects, zidovudine (one of the active ingredients) has shown some risks in animal studies. Individuals who take this medication while pregnant are encouraged to participate in the Antiretroviral Pregnancy Registry, which monitors health outcomes for both the parent and the child.

Breastfeeding

In general, health experts recommend that individuals with HIV avoid breastfeeding for the following reasons:

• The HIV virus can be passed to the infant through breast milk.
• The active ingredients in Combivir, lamivudine and zidovudine, are known to pass into breast milk and may cause side effects in the nursing infant.

It is important to discuss the safest infant feeding options and the potential risks of medication exposure with a healthcare professional.

Available Forms

Combivir is supplied as a film-coated tablet intended for oral administration. This medication is a fixed-dose combination product, meaning it contains two active ingredients in one tablet.

• Oral tablet

FDA Approval Status

Combivir, a fixed-dose combination of lamivudine and zidovudine, was approved by the U.S. Food and Drug Administration (FDA) in 1997. It is indicated for the treatment of HIV-1 infection when used as part of a combination antiretroviral regimen. It is approved for use in adults and pediatric patients weighing at least 30 kilograms.

Boxed Warnings

The FDA has issued boxed warnings for Combivir due to the following serious safety concerns:

• Hematologic Toxicity: The zidovudine component has been associated with severe anemia and neutropenia (low white blood cell count), particularly in patients with advanced HIV disease.
• Myopathy: Long-term use of zidovudine has been linked to symptomatic muscle disease and weakness.
• Lactic Acidosis and Hepatomegaly: Fatal cases of lactic acidosis and severe liver enlargement with fatty liver (steatosis) have been reported with the use of nucleoside analogues.
• Exacerbations of Hepatitis B: Patients co-infected with HIV-1 and hepatitis B (HBV) may experience severe, acute flare-ups of hepatitis B if they stop taking medications containing lamivudine. Liver function must be closely monitored in these patients.

Generic Availability

Generic versions of the lamivudine and zidovudine combination are FDA-approved and available in the United States. These generic products are required to meet the same standards for quality, strength, and purity as the brand-name medication.

Generic Availability

Generic versions of Combivir, which contain the active ingredients lamivudine and zidovudine, are available. Generic medications are typically less expensive than brand-name drugs while maintaining the same standards for safety and effectiveness.

Insurance and Coverage

Most health insurance plans, including Medicare and Medicaid, cover the generic form of this medication. The actual out-of-pocket cost will depend on your specific insurance plan, including your deductible, copayment, or coinsurance requirements.

Factors Affecting Price

Several factors can influence the final price of this medication:

• Pharmacy Selection: Prices can differ between retail pharmacies, online pharmacies, and mail-order services.
• Prescription Volume: Purchasing a 90-day supply may sometimes result in a lower cost per dose compared to a 30-day supply.
• Assistance Programs: Some patients may be eligible for financial assistance through manufacturer programs or non-profit organizations if they are uninsured or have high out-of-pocket costs.